bioRxivCancer BiologyPreprint
Distinct Progression Paths Underlie the Diversity of Pancreatic Papillary Cystic Neoplasms
Camille PignoletiD, Lina Aguilera MunoziD, Lucy Bourlet, Taib Bourega, Lucie Gomes, Diana MendesiD, Nathalie Théou–AntoniD, Nathalie ColnotiD, Miguel AlbuquerqueiD, Louis de Mestier, Safi DokmakiD, Anne CouvelardiD, Vinciane ReboursiD, Rémy NicolleiD, Jerome F. CrosiD
Abstract
Surgical decisions for intraductal papillary mucinous neoplasms (IPMNs), precursors of pancreatic cancer, depend on distinguishing low- from high-grade dysplasia, a distinction that molecular markers could refine. We microdissected 433 tumor regions from 135 patients and integrated transcriptomics, deep-learning histology, and KRAS/GNAS RNA-called variants. RNA programs and morphological motifs separated lesions by phenotype, intestinal versus others, rather than by dysplasia grade. Along gastric IPMN trajectories, low-grade lesions recapitulated the pit-chief polarity of normal gastric glands, whereas high-grade lesions were indistinguishable from pancreatobiliary lesions in morphology, RNA programs, and driver mutations. Intestinal IPMNs arose through two routes: a canonical GNAS-associated pathway and a KRAS-associated shift from low-grade gastric features, with lesions sharing driver mutations retaining common programs across phenotypes. Resolving these phenotypic trajectories clarified distinct progression paths and enabled phenotype-specific prediction of high-grade dysplasia in mucus aspirated from 94 resected lesions. These findings support a promising fluid-based assessment of IPMN status.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: trajectory inference
- approach: deep learning
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
A. Semaan, V. Bernard, … P. A. Guerrero·bioRxiv·Oct 14, 2022
- Mutant GNAS drives a pyloric metaplasia with tumor suppressive glycans in intraductal papillary mucinous neoplasia
Vincent Quoc‐Huy Trinh, Katherine E. Ankenbauer, … Kathleen E. DelGiorno·bioRxiv·Feb 25, 2024
- Digital Spatial Profiling of Intraductal Papillary Mucinous Neoplasms: Towards a Molecular Framework for Risk Stratification
P. J. Allen, M. K. Iyer, … D. P. Nussbaum·bioRxiv·Sep 8, 2022
- Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
M. Sans, Y. Makino, … A. Maitra·Cancer DiscoveryPeer-reviewed·Jun 7, 2023
- Spatial analysis of IPMNs defines a paradoxical KRT17-positive, low-grade epithelial population harboring malignant features
Jay Li, Georgina Branch, … Eileen S. Carpenter·Cellular and Molecular Gastroenterology and HepatologyPeer-reviewed·Jan 1, 2026
- Transcriptomic dissection of Intraepithelial Papillary Mucinous Neoplasms progression by spatial technologies identified novel markers of pancreatic carcinogenesis.
A. Agostini, G. Piro, … C. Carbone·bioRxiv·Oct 12, 2022